FAQs on the Use of Asparaginase Therapy in Young and Older Adults With Acute Lymphoblastic Leukemia

In this episode, Daniel J. DeAngelo, MD, PhD; Kjeld Schmiegelow, MD, DMSci; and Emily Curran, MD, answer key questions asked by the audience during a live satellite symposium at the 2022 American Society of Hematology Annual Meeting on optimizing pediatric or pediatric-inspired regimens containing asparaginase for the treatment of young and older adults with acute lymphoblastic leukemia.

Topics discussed include:

• Practical considerations for management of allergy-like reactions and hypersensitivity to asparaginase
• Indirect methods for measuring asparaginase activity
• Strategies to mitigate adverse events with asparaginase treatment, including hepatotoxicity, pancreatitis, and thrombosis
• Considerations for use of asparaginase in special populations (eg, high BMI, older age)

Presenters:

Program Director
Daniel J. DeAngelo, MD, PhD
Professor of Medicine
Department of Medicine
Harvard Medical School
Chief of the Division of Leukemia
Department of Medical Oncology
Division of Hematologic Malignancies
Dana‐Farber Cancer Institute
Boston, Massachusetts

Emily Curran, MD
Assistant Professor
Division of Hematology/Oncology
University of Cincinnati Cancer Institute
Cincinnati, Ohio

Kjeld Schmiegelow, MD, DMSci
Professor
Department of Pediatric Oncology
Righospitalet University Hospital
Copenhagen, Denmark

Content based on an online CME program supported by an independent educational grant from Jazz Pharmaceuticals.

Link to full program:
http://bit.ly/3YXkLyj

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.